




Telbivudine

Revised: April 15, 2023.

CASRN: 3424-98-4



Drug Levels and Effects

Summary of Use during Lactation

Telbivudine has been discontinued from the US market. It has not been studied in nursing mothers being treated for hepatitis B infection. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.

No difference exist in infection rates between breast-fed and formula-fed infants born to hepatitis B-infected women, as long as the infant receives hepatitis B immune globulin and hepatitis B vaccine at birth. Mothers with hepatitis B are encouraged to breastfeed their infants after their infants receive these preventative measures.[1,2]

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Hepatitis B) [Interferon Alfa](#), [Lamivudine](#), [Tenofovir](#)

References

1. Visvanathan K, Dusheiko G, Giles M, et al. Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: Position paper produced by Australian, UK and New Zealand key opinion leaders. *Gut*. 2016;65:340–50. PubMed PMID: 26475631.
2. Dionne-Odom J, Tita AT, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. *Am J Obstet Gynecol*. 2016;214:6–14. PubMed PMID: 26454123.

Substance Identification

Substance Name

Telbivudine

CAS Registry Number

3424-98-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Antiviral Agents

Nucleic Acid Synthesis Inhibitors